Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Life Sciences
Findings in life sciences reported from University of Tubingen
December 31st, 2008
According to recent research published in the journal Cell Cycle, "Adoptive transfer of tumor antigen-specific T helper (Th) cells is a surprisingly potent anti-tumor therapy. Even in RIP1-Tag2 mice with a rapidly growing, aggressive endogenous beta cell tumor Th can significantly extend life time and are more efficient than any other therapy studied." "The therapeutic effect of Th cells seems to be independent of tumor cell destruction. It critically relies on three principles: (1) inhibition of tumor angiogenesis, (2) inhibition of beta cell proliferation, and (3) induction of tumor dormancy. As tumor cell destruction by cytotoxic CD8(+) T cells (CTL) largely...
Source: Vaccine Weekly (2008-12-31)
|
